Cure8 trial brief
Real-world PSP registries can show how long people stay on vedolizumab and how it’s used alongside or compared with other advanced therapies like tofacitinib. That information can help patients and clinicians understand treatment persistence outside clinical trials.
Adults with IBD (Crohn’s disease or ulcerative colitis), patients receiving vedolizumab, clinicians who prescribe biologics, researchers studying real-world biologic use and treatment persistence.
This is a completed, non-interventional observational study (patient support program registry) of adults with ulcerative colitis or Crohn’s disease in Brazil who received vedolizumab IV or SC.
The study collected retrospective and prospective PSP data to measure treatment persistence and related real-world outcomes; tofacitinib and other advanced therapies were listed for comparison of persistence.
The record describes enrollment cohorts, inclusion criteria, planned enrollment, primary outcome (treatment persistence up to ~9 years), and that no interventional treatment was administered as part of the study. The data source is the PSP database in Brazil and the study duration was ~26 months for the observational follow-up.
Because this is an observational registry record, it reports study design and outcomes of interest rather than trial-driven efficacy results or safety findings. For individual treatment decisions, patients should consult their care team and look for published analyses from the registry.
This is a registry/observational study record from ClinicalTrials.gov (sponsored by Takeda) describing design and planned/collected endpoints; it does not itself present detailed study results in this record. As an observational PSP review, data quality depends on program records and participant-reported information.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...
Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and...
